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Isocyanurate Formation During Oxazolidinone Synthesis from 
Epoxides and Isocyanates Catalysed by a Chromium(Salphen) 
Complex 
 Xiao Wu,[a] Jess Mason[a] and Michael North*[a] 
 
Abstract: Chromium(salphen) complex 10 is found to be a catalyst 
for the preparation of oxazolidinones from epoxides and isocyanates. 
Using the optimal reaction conditions (1.5 mol% of 
chromium(salphen) complex 10 at 80 oC in toluene for 4 hours), six 
epoxides were reacted with five isocyanates, providing 15 
oxazolidinones in up to 90% yield. With electron-deficient 
isocyanates, cyclotrimerisation of the isocyanate to the 
corresponding isocyanurates is a competing reaction, showing the 
importance of matching catalyst activity to that of the substrates. 
Introduction 
Epoxides 1 are useful building blocks in organic synthesis and a 
number of five-membered heterocycles can be prepared when 
they are treated with heterocumulenes. The reaction with carbon 
dioxide to furnish either cyclic- or poly-carbonates 2 and 3 has 
been extensively studied.1,2,3 Other areas of interest include the 
formation of either cyclic dithiocarbonates 4 or trithiocarbonates 
5,4 and oxazolidinones 6 and 75 (Scheme 1). 
 
Scheme 1. Synthesis of heterocycles from epoxides and heterocumulenes. 
Oxazolidinones are an important class of heterocycles and 
have been found to be useful compounds in medicinal 
chemistry,6 as well as being valuable synthetic intermediates.7 
The reaction of epoxides with isocyanates is one of the most 
useful and efficient methods for the synthesis of oxazolidinones 
(Scheme 1). A number of catalyst systems have been reported 
for this reaction, including ammonium salts,8 lanthanide salts,9 
lithium halides,10 magnesium halides,11 tetraphenylantimony 
iodide12 and trialkyltin halides.13 
Recently, our group has reported a number of highly 
efficient metal-based catalysts 8±10 for the formation of cyclic 
carbonates from epoxides and carbon dioxide (Figure 1).14,15,16 
Compounds 8 and 9 also exhibit excellent catalytic activity for 
the preparation of oxazolidinones.5a,b Thus, 5 mol% of bimetallic 
aluminium(salen) complex 8 in the absence of a co-catalyst was 
found to be an active catalytic system for the synthesis of a 
range of mono- and di-substituted oxazolidinones. In the 
presence of tetrabutylammonium bromide (5 mol%), aluminium 
heterosorpionate complex 9 (5 mol%) was also shown to be an 
effective catalyst for the preparation of oxazolidinones. Six 
epoxides were reacted with six aromatic isocyanates to give 25 
oxazolidinones, showing a broad substrate scope. 
 
Figure 1. Catalysts for the synthesis of cyclic carbonates and oxazolidinones. 
More recently, our group has reported the synthesis of 
cyclic carbonates from epoxides and carbon dioxide using 
chromium(salphen) complex 10.16 In this case, only 1.5 mol% of 
complex 10 was necessary to catalyse the synthesis of a range 
of cyclic carbonates, either from monosubstituted epoxides at 
room temperature and one bar carbon dioxide pressure, or from 
disubstituted epoxides at elevated temperature and pressure. In 
view of the high catalytic activity shown by complex 10, we 
decided to investigate its use in the related reaction between 
epoxides and isocyanates. Herein, we report the use of 
chromium(salphen) complex 10 as an efficient catalyst for the 
formation of oxazolidinones from epoxides and isocyanates. 
[a] Dr. X. Wu, Miss J. Mason, Professor M. North 
Green Chemistry Centre of Excellence, Department of Chemistry 
University of York 
Heslington, York, YO10 5DD 
E-mail: Michael.north@york.ac.uk 
 Supporting information for this article is given via a link at the end of 
the document. 
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Results and Discussion 
Screening studies were carried out using styrene oxide 1a and 
phenyl isocyanate 11a in a 1:1 ratio under various reaction 
conditions (Scheme 2) and the results are shown in Table 1. 
Initial experiments were undertaken using 1.5 mol% of both 
chromium(salphen) complex 10 and tetrabutylammonium 
bromide (TBAB) as a co-catalyst at 80 oC for 24 hour under 
solvent-free conditions (Table 1, entry 1). However, the reaction 
mixture solidified after 30 minutes. This suggested that a solvent 
was necessary to increase the conversion to the oxazolidinone 
products. Toluene was selected based on literature precedent5a,b 
and the reaction mixture was heated to 80 oC. After 24 hours, 
75% conversion was obtained (Table 1, entry 2). Control 
experiments proved to be very informative. In the absence of 
TBAB, chromium(salphen) complex 10 was able to catalyse the 
reaction itself and a 90% conversion was achieved, whereas in 
the absence of complex 10, only 7% conversion was observed 
(Table 1, entries 3 and 4). Increasing the catalyst loading to 2.5 
mol% was not beneficial while lowering the catalyst loading to 
0.5 mol% resulted in low conversion (Table 1, entries 5 and 6). 
To further optimise the reaction conditions, a sample was taken 
after each hour and it was found that the reaction reached 
maximum conversion after 4 hours. It was therefore decided that 
1.5 mol% of catalyst 10 and heating in toluene at 80 oC for 4 
hours were the optimal reaction conditions for the synthesis of 
oxazolidinones from epoxides and isocyanates. 
 
Scheme 2. Reaction of styrene oxide 1a with phenylisocyanate 11a. 
Table 1. Optimisation of the synthesis of oxazolidinones 6a and 7a using 
complex 10 and TBAB. 
Entry Complex 10 (mol%) 
TBAB 
(mol%) 
t 
(h) 
Toluene 
(mL) 
Conversion[a] 
(%) 6a:7b
[a]
 
1 1.5 1.5 24 0 70 50:50 
2 1.5 1.5 24 0.5 75 66:34 
3 1.5 0 24 0.5 90 35:65 
4 0 1.5 24 0.5 7 75:25 
5 2.5 0 24 0.5 88 50:50 
6 0.5 0 24 0.5 28 50:50 
7 1.5 0 4 0.5 90 35:65 
[a] Conversion of epoxide 1a into 6a and 7a and ratio of 6a:7a were 
determined by 1H NMR spectroscopy of the unpurified reaction mixture. 
Having determined the optimal reaction conditions for the 
synthesis of oxazolidinones 6a and 7a from styrene oxide 1a 
and phenyl isocyanate 11a, a series of epoxides was used 
together with phenyl isocyanate 11a to give oxazolidinones 6b-g 
and 7b-g (Scheme 3). The results of this study are shown in 
Table 2. Functionalised aliphatic epoxides (3-
phenoxypropropylene oxide 1b and epichlorohydrin 1c) and 
unfunctionalised aliphatic epoxide 1d were all excellent 
substrates, giving high conversions and excellent regioselectivity 
to the 3,5-isomers 6b-d (Table 2, entries 2-4). In contrast, 
glycidol 1e was found to be a poor substrate, giving a complex 
mixture from which no product could be isolated (Table 2, entry 
5). When aromatic epoxides 1f and 1g, containing a halogen at 
the para-position were used as substrates, good conversions 
were obtained though with no regioselectivity (Table 2, entries 6 
and 7). 
 
Scheme 3. Reaction of epoxides 1a-g with phenylisocyanate 11a. 
Table 2. Synthesis of oxazolidinone 6a-g and 7a-g using epoxide 1a-g.[a] 
Entry Epoxide Conversion[b] (%) Yield[c] (%)  
1 1a R1 = Ph 90 (35:65) 6a,7a (65)  
2 1b R1 = CH2OPh 80 (1:0) 6b (62)  
3 1c R1 = CH2Cl 100 (1:0) 6c (90)  
4 1d R1 = C8H17 100 (92:8) 6d (59)  
5 1e R1 = CH2OH 0 -  
6 1f R1 = 4-ClC6H4 75 (1:1) 6f, 7f (59)  
7 1g R1 = 4-BrC6H4 70 (1:1) 6g, 7g (62)  
[a] Reactions were carried out using 1.5 mol% chromium(salphen) 
complex 10 in toluene at 80 oC for 4 hours. [b] Determined by 1H NMR 
spectroscopy of the unpurified reaction mixture and figure in brackets is 
the ratio of 6:7. [c] Yield of isolated product after purification by column 
chromatography. 
 
To further expand the substrate scope, styrene oxide 1a 
and epichlorohydrin 1c were selected as representative aromatic 
and aliphatic epoxides respectively for the synthesis of 
oxazolidinones from various isocyanates (Scheme 4). Five 
substituted aromatic isocyanates 11b-f and two aliphatic 
isocyanates 11g and 11h were reacted with these epoxides and 
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the results are summarised in Table 3. It was found that 
aromatic isocyanates 11b,c gave good to excellent conversions 
after 4 hours. A 1:1 ratio of 3,4- and 3,5- regioisomers was 
observed when styrene oxide 1a was used, while with 
epichlorohydrin 1c, complete regioselectivity for the 3,5-isomer 
was achieved (Table 3, entries 1-5 and 8-12). In comparison, no 
conversion was obtained when aliphatic isocyanates 11g,h were 
used (entries 6,7 and 13,14). With aromatic isocyanates that 
have halogen groups at the para-position, chromium(salphen) 
complex 10 was found to catalyse the formation of both 
oxazolidinones and isocyanurates (perhydro-1,3,5-triazine-2,4,6-
triones) 12 (Figure 2) (Table 3, entries 3-5). Isocyanurates are 
known to enhance the physical properties of polyurethanes and 
coating materials,17 typically by increasing their flame retardation 
and filming characteristics, and commercial products containing 
polymeric isocyanurates have increased chemical and thermal 
resistance.18 
 
Scheme 4. Reaction of epoxides 1a,c with isocyanate 11a-h. 
 
Figure 2. Structure of isocyanurates 12 and urea 13. 
Isocyanurates have previously been prepared by the 
cyclotrimerisation of isocyanates catalysed by species including 
organotin19 and organozinc compounds,20 copper and nickel 
halides21 and palladium,22 magnesium23 and iron complexes.0 
The formation of isocyanurates 12a-c was much less important 
when the competing reaction was between epichlorohydrin 1c 
and isocyanates than when styrene oxide 1a was used. 
However, since the separation of oxazolidinones 6q-s from 
isocyanurates 12a-c proved difficult, the isolated yields of these 
oxazolidinones were less than satisfactory (Table 3, entries 10-
12). The formation of isocyanurates as by-products from the 
reaction between epoxides and isocyanates has not previously 
been reported. A control experiment using 4-fluorophenyl 
isocyanate 11d in the presence of chromium complex 10 under 
the standard reaction conditions but in the absence of an 
epoxide also gave isocyanurate 12a, indicating that chromium 
complex 10 is a strong Lewis acid and capable of catalysing the 
cyclotrimerisation of isocyanates. In the absence of chromium 
complex 10, only the starting material 4-fluorophenyl isocyanate 
was recovered. When isocyanates that have an electron-
donating substituent at the para-position such as 11b were used, 
the corresponding urea 13 was isolated rather than the 
isocyanurate. 
 
Table 3. Synthesis of oxazolidinones 6,7h-u using complex 10.[a] 
Entry Epoxide Isocyanate Conv.
[b] 
(%) Yield
[c]
 (%) 
1 1a R1 = Ph 11b R2 = 4-MeOC6H4 60 (1:1) 6h, 7h (56) 
2 1a R1 = Ph 11c R2 = 4-MeC6H4 90 (1:1) 6i, 7i (62) 
3 1a R1 = Ph 11d R2 = 4-FC6H4 30 (1:1)  7j (12)[d] 
4 1a R1 = Ph 11e R2 = 4-ClC6H4 22 (1:1) 7k (10)[e] 
5 1a R1 = Ph 11f R2 = 4-BrC6H4 23 (1:1) 7l(10)[f] 
6 1a R1 = Ph 11g R2 = CH2Ph 0  
7 1a R1 = Ph 11h R2 = Et 0  
8 1c R1 = CH2Cl 11b R2 = 4-MeOC6H4 98 (1:0) 6o (80) 
9 1c R1 = CH2Cl 11c R2 = 4-MeC6H4 96 (1:0) 6p (83) 
10 1c R1 = CH2Cl 11d R2 = 4-FC6H4 90 (1:0) 6q (21)[g] 
11 1c R1 = CH2Cl 11e R2 = 4-ClC6H4 85 (1:0) 6r (42) 
12 1c R1 = CH2Cl 11f R2 = 4-BrC6H4 90 (1:0) 6s (36) 
13 1c R1 = CH2Cl 11g R2 = CH2Ph 0  
14 1c R 1= CH2Cl 11h R2 = Et 0  
[a] Reactions were carried out using 1.5 mol% of chromium(salphen) 
complex 10 in toluene at 80 oC for 4 hours. [b] Conversion of epoxides to 
oxazolidinones 6,7 determined by 1H NMR spectroscopy of the 
unpurified reaction mixture and figure in brackets is the ratio of 6:7. [c] 
Yield of isolated product after purification by column chromatography. [d] 
Mixture of oxazolidinone 7j and isocyanurate 12a in 40:60 ratio. [e] Mixture of 
oxazolidinone 7k and isocyanurate 12b in 45:55 ratio. [f] Mixture of 
oxazolidinone 7l and isocyanurates 12c in 50:50 ratio. [g] Mixture of 
oxazolidinone 6q and isocyanurate 12a in 95:5 ratio. 
 
The chemo- and regio-selectivities observed when using 
complex 10 as a catalyst can be explained by the catalytic 
cycles shown in Scheme 5. Complex 10 can act both as a Lewis 
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acid and as a source of a good nucleophile (chloride). 
Substrates 1 and 11 possess three sites which are susceptible 
to nucleophilic attack: both ends of the epoxide and the central 
carbon atom of the isocyanate. They also possess two sites for 
Lewis acid activation: the epoxide oxygen and the isocyanate 
oxygen. For oxazolidinone formation, the chromium(salphen) 
species first acts as a Lewis acid, activating the epoxide towards 
ring-opening by chloride anion. The regioselectivites observed 
with epoxides 1a-g are consistent with ring-opening of the 
activated epoxide normally occurring at the less-hindered, 
unsubstituted position by an SN2 type mechanism, eventually 
giving the 3,5-isomer of the oxazolidinone. However, when R1 is 
an aromatic group capable of stabilising a benzylic carbenium 
ion, then ring-opening of the epoxide at the more-hindered, 
substituted position ultimately leading to the 3,4-isomer of the 
oxazolidinone becomes competitive and little or no 
regioselectivity is observed. The chromium coordinated alkoxide 
then reacts with the isocyanate to form a carbamate and this 
ring closes to give oxazolidinone 6 or 7 with regeneration of 
catalyst 10. For isocyanurate formation, the isocyanate oxygen 
atom coordinates competitively to the metal centre, followed by 
the nucleophilic attack of the chloride anion to give a chromium 
complexed carbomoyl chloride complex A. Following this, the 
nucleophilic nitrogen can then react further with two molecules 
of isocyanates before ring-closing with elimination of chloride to 
form isocyanurates 12 and regenerate catalyst 10. 
Conclusions 
Chromium(salphen) complex 10 was found to catalyse the 
formation of oxazolidinones from epoxides and isocyanates in 
the absence of a co-catalyst. Compared to previously reported 
aluminium(salen) complexes, chromium(salphen) complex 10 
appears to be more Lewis acidic. This allows the catalyst 
loading to be reduced to 1.5 mol% and the reaction time to be 
reduced to 4 hours. However, the enhanced Lewis acidity of 
complex 10 causes the reaction to take a different pathway with 
electron-deficient isocyanates, leading to the formation of 
isocyanurates 12 by a pathway that involves Lewis acid 
activation and subsequent trimerisation of the isocyanate rather 
than Lewis acid activation of the epoxide. These results illustrate 
that although a strongly Lewis acidic catalyst is desirable to 
activate the epoxide for the formation of oxazolidinones from 
epoxides and isocyanates, the optimal catalyst for the process is 
substrate dependent and requires the electronic properties of 
both substrates and catalyst to be matched. 
Experimental Section 
Catalyst 10 was prepared as previously reported.16 All 
other compounds were commercially available and used as 
supplied. 1H NMR and 13C NMR were recorded in CDCl3 at 25 
oC on a JEOL 400 spectrometer operating at 400 and 100 MHz, 
respectively. Melting points were determined using a Stuart 
SMP3 apparatus. Infrared spectra were recorded on a Bruker 
Vertex 70 instrument. 
 
Scheme 5. Proposed catalytic cycles for the synthesis of oxazolidinones and 
isocyanurates induced by chromium(salphen) complex 10. 
General procedure for oxazolidinone synthesis 
Epoxide 1a_g (0.83 mmol) and isocyanate 11a_h (0.83 mmol) 
were added to a solution of catalyst 10 (0.013 mmol) in toluene 
(0.5 mL). The resulting mixture was stirred at 80 oC for 4 hours. 
After being allowed to cool to room temperature, toluene was 
removed under pressure to give the crude oxazolidinone 
products. The conversion of epoxide to oxazolidinone was 
determined by 1H NMR spectroscopy of the crude mixture. The 
products were purified by flash chromatography to give 
compound 6/7 a-s. 
3,5-Diphenyloxazolidin-2-one (6a): Obtained as a yellow solid 
after purification by flash chromatography using a solvent 
system of first hexane±EtOAc (5:1), then hexane±EtOAc (3:1). 
(85 mg, 43%). M.p. 80±82 oC (lit. 79±82 oC).[5a] 1H NMR (400 
MHz, CDCl3) G 7.56 (2H, d, J 8.0 Hz, ArH), 7.46±7.37 (7H, m, 
ArH), 7.15 (1H, t, J 8.0 Hz, ArH), 5.65 (1H, d, J 8.0, CHO), 4.39 
(1H, t, J 8.0 Hz, CH2N), 3.98 (1H, t, J 8.0 Hz, CH2N); 13C (100 
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MHz, CDCl3) G 154.7, 138.1, 138.0, 129.1, 129.0, 125.7, 124.2, 
118.3, 74.0, 52.7. Mass spec. (ESI): calcd. m/z 240.1019 
[C15H14NO2]+; found: 240.1013. calcd. m/z 262.0838 
[C15H13NO2+Na]+; found: 262.0831. IR (neat, cm-1): 1745. 
3,4-Diphenyloxazolidin-2-one (7a): Obtained as a yellow solid 
after purification by flash chromatography using a solvent 
system of first hexane±EtOAc (5:1), then hexane±EtOAc (3:1). 
(44 mg, 22%). M.p. 80±82 oC (lit. 79±82 oC).[5a] 1H NMR (400 
MHz, CDCl3) G 7.40±7.28 (9H, m, ArH), 7.07 (1H, t, J 8.0 Hz, 
ArH), 7.15 (1H, t, J 7.4 Hz, ArH), 5.40 (1H, dd, J 8.0, 6.0 Hz, 
CHN), 4.79 (1H, t, J 8.0 Hz, CH2O), 4.21 (1H, dd, J 8.0, 6.0 Hz, 
CH2O); 13C (100 MHz, CDCl3) G 155.9, 138.2, 137.0, 129.4, 
128.9, 128.8, 126.2, 120.8, 69.8, 60.7. Mass spec. (ESI): calcd. 
m/z 240.1019 [C15H14NO2]+; found: 240.1024. calcd. m/z 
262.0838 [C15H13NO2+Na]+; found: 262.0842. IR (neat, cm-1): 
1741. 
3-Phenyl-5-phenoxymethyloxazolidin-2-one (6b): Obtained as  
a yellow solid after purification by flash chromatography using a 
solvent system of first hexane±EtOAc (3:1), then hexane±EtOAc 
(2:1) (218 mg, 93%). M.p. 138±141 oC (lit. 139±140 oC).[5a] 1H 
NMR (400 MHz, CDCl3) G 7.58 (2H, d, J 8.0 Hz, ArH), 7.40 (2H, t, 
J 8.0 Hz, ArH), 7.30 (2H, t, J 8.0 Hz, ArH), 7.16 (1H, t, J 8.0 Hz, 
ArH), 7.00 (1H, t, J 8.0 Hz, ArH), 6.91 (2H, d, J 8.0 Hz, ArH), 
5.09±4.96 (1H, m, CHO), 4.24±4.19 (3H, m, CH2O, CH2N), 4.09 
(1H, dd, J 8.0, 4.0 Hz, CH2N); 13C (100 MHz, CDCl3) G 158.0, 
154.4, 138.1, 129.6, 129.1, 124.2, 121.7, 118.3, 114.6, 70.3, 
67.8, 47.4. Mass spec. (ESI): calcd. m/z 292.0944 
[C16H15NO3+Na]+; found: 292.0939. IR (neat, cm-1): 1732. 
3-Phenyl-5-chloromethyloxazolidin-2-one (6c): Obtained as a 
pale yellow solid after purification by flash chromatography using 
a solvent system of hexane±EtOAc (2:1) (158 mg, 90%). M.p. 
108±110 oC (lit. 101±103 oC).[5a] 1H NMR (400 MHz, CDCl3) G 
7.56 (2H, m, ArH), 7.40 (2H, t, J 8.0 Hz, ArH), 7.17 (1H, t, J 8.0 
Hz, ArH), 4.91±4.85 (1H, m, CHO), 4.18 (1H, t, J 8.0, Hz, CH2N), 
3.97 (1H, dd, J 8.0, 4.0 Hz, CH2N), 3.81 (1H, dd, J 12.0, 4.0 Hz, 
CH2Cl), 3.75 (1H, dd, J 12.0, 4.0 Hz, CH2Cl); 13C (100 MHz, 
CDCl3) G 153.9, 137.7, 129.2, 124.4, 118.3, 70.8, 48.2, 44.5. 
Mass spec. (ESI): calcd. m/z 234.0292 [C10H10ClNO2+Na]+; 
found: 234.0296. IR (neat, cm-1): 1728. 
3-Phenyl-5-octyloxazolidin-2-one (6d): Obtained as a white 
solid after purification by flash chromatography using a solvent 
system of hexane±EtOAc (9:1) (135 mg, 59%). M.p. 71±73 oC 
(lit. 70± 71 oC).[5a] 1H NMR (400 MHz, CDCl3) G 7.54 (2H, d, J 8.0 
Hz, ArH), 7.37 (2H, t J 8.0 Hz, ArH), 7.13 (1H, t, J 8.0 Hz, ArH), 
4.66±4.61 (1H, m, CHO), 4.08 (1H, t, J 8.0 Hz, CH2N), 3.66 (1H, 
dd, J 8.0, 7.5 Hz, CH2N), 1.91±1.68 (2H, m, CH2), 1.42±1.22 
(12H, m, 6×CH2), 0.90 (3H, t, J 8.0 Hz, CH3); 13C (100 MHz, 
CDCl3) G 155.0, 138.4, 129.0, 123.9, 118.1, 73.1, 50.5, 35.0, 
31.8, 29.4, 29.2, 29.1, 24.5, 22.6, 14.1. Mass spec. (ESI): Calcd. 
m/z 298.1777 [C17H25NO2+Na]+; found:298.1767.  IR (neat, cm-
1): 1717. 
3-Phenyl-5-(4-chlorophenyl)-oxazolidin-2-one (6f): Obtained 
as a pale yellow solid after purification by flash chromatography 
using a solvent system of CH2Cl2±hexane (4:1) (68 mg, 30%). 
M.p. 124±125 oC (lit. 124±126 oC).[5b] 1H NMR (400 MHz, CDCl3) 
G 7.55 (2H, d, J 8.0 Hz, ArH), 7.43±7.36 (6H, m, ArH), 7.16 (1H, t, 
J 8.0 Hz, ArH), 5.63 (1H, t, J 8.0 Hz, CHO), 4.39 (1H, t, J 8.0 Hz, 
CH2N), 3.93 (1H, dd, J 8.0, 7.5 Hz, CH2N); 13C (100 MHz, 
CDCl3) G 154.4, 137.9, 136.6, 135.0, 129.3, 129.1, 127.1, 124.3, 
118.3, 73.3, 52.6. Mass spec. (ESI): Calcd. m/z 296.0449 
[C15H12ClNO2+Na]+; found: 296.0449. IR (neat, cm-1): 1733. 
3-Phenyl-4-(4-chlorophenyl)-oxazolidin-2-one (7f): Obtained 
as a pale yellow solid after purification by flash chromatography 
using a solvent system of CH2Cl2±hexane (4:1) (66 mg, 29%). 
M.p. 140±143 oC (lit. 140±142 oC).[5b]  1H NMR (400 MHz, 
CDCl3) G 7.37±7.24 (8H, m, ArH), 7.11±7.07 (1H, m, ArH), 5.38 
(1H, dd, J 12.0, 8.0 Hz, CHN), 4.78 (1H, t, J 12.0 Hz, CH2O), 
4.17 (1H, dd, J 8.0, 4.0 Hz, CH2O); 13C (100 MHz, CDCl3) G 
155.7, 139.4, 136.7, 134.9, 129.6, 129.0, 127.6, 124.9, 120.9, 
69.6, 60.1. Mass spec. (ESI): calcd. m/z 274.0629 
[C15H13ClNO2]+; found: 274.0633. Calcd. m/z 296.0449 
[C15H12ClNO2+Na]+; found: 296.0448. IR (neat, cm-1): 1733. 
3-Phenyl-5-(4-bromophenyl)-oxazolidin-2-one (6g): Obtained 
as a white solid after purification by flash chromatography using 
a solvent system of first hexane±EtOAc (7:1), then hexane±
EtOAc (4:1), then hexane±EtOAc (3:1), (77 mg, 30%). M.p 132±
134 oC (lit. 132±134 oC).[5b]  1H NMR (400 MHz, CDCl3) G 7.58±
7.53 (4H, m, ArH), 7.41±7.37 (2H,m, ArH), 7.32±7.29 (2H, m, 
ArH), 7.18±7.14 (1H, m, ArH), 5.61 (1H, t, J 8.0 Hz, CHO), 4.39 
(1H, t, J 8.0 Hz, CH2N), 3.92 (1H, dd, J 8.0, 7.5 Hz, CH2N); 13C 
(100 MHz, CDCl3) G 154.3, 137.8, 137.1, 132.2, 129.2, 127.3, 
124.4 123.2, 118.3, 73.3, 52.5. Mass spec. (ESI): calcd. m/z 
339.9944 [C15H12BrNO2+Na]+; found: 339.9940. IR (neat, cm-1): 
1726. 
3-Phenyl-4-(4-bromophenyl)-oxazolidin-2-one (7g): Obtained 
as a yellow solid after purification by flash chromatography using 
a solvent system of first hexane±EtOAc (7:1), then hexane±
EtOAc(4:1), then hexane-EtOAc (3:1), (82 mg, 32%). M.p. 157±
158 oC (lit. 156±158 oC).[5b]  1H NMR (400 MHz, CDCl3) G 7.49 
(2H, d, J 8.0 Hz, ArH), 7.37_7.25 (4H, m, ArH), 7.19 (2H, d, J 8.0, 
ArH), 7.10 (1H, m, ArH), 5.37 (1H, dd, J 8.0, 6.0 Hz, CHN), 4.78 
(1H, t, J 8.0 Hz, CH2O), 4.17 (1H, dd, J 8.0, 6.0 Hz, CH2O); 13C 
(100 MHz, CDCl3) G 155.7, 137.2, 132.6, 129.2, 129.0, 127.9 
125.0, 120.8, 116.5, 69.5, 60.1. Mass spec. (ESI): calcd. m/z 
339.9944 [C15H12BrNO2+Na]+; found: 339.9943. IR (neat, cm-1): 
1728. 
3-(4-Methoxyphenyl)-5-phenyloxazolidin-2-one (6h): 
Obtained as a pale yellow solid after purification by flash 
chromatography using a solvent system of hexane:EtOAc (5:1) 
(66 mg, 28%). M.p. 100±102 oC (lit. 105±107 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.46±7.38 (7H, m, ArH), 6.93±6.91 (2H, m, 
ArH), 5.63 (1H, t, J 8.0 Hz, CHO), 4.35 (1H, t, J 8.0 Hz, CH2N), 
3.94 (1H, dd, J 12.0, 8.0 Hz, CH2N), 3.80 (3H, s, OCH3); 13C 
(100 MHz, CDCl3) G 156.4, 155.0, 138.2, 131.3, 129.0, 128.9, 
125.6, 120.3, 114.3, 74.0, 55.5, 53.3. Mass spec. (ESI): calcd. 
m/z 292.0944 [C16H15ClNO2+Na]+; found: 292.0933. IR (neat, 
cm-1): 1732. 
3-(4-Methoxyphenyl)-4-phenyloxazolidin-2-one (7h): 
Obtained as a pale yellow solid after purification by flash 
chromatography using a solvent system of hexane±EtOAc (5:1) 
(66 mg, 28%). M.p. 134±136 oC (lit. 137±138 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.35±7.23 (7H, m, ArH), 6.78 (2H, d, J 8.0 
Hz, ArH), 5.31 (1H, dd, J 8.0, 6.0 Hz, CHN), 4.77 (1H, t, J 8.0 Hz, 
CH2O), 4.22 (1H, dd, J 8.0, 6.0 Hz, CH2O), 3.73 (3H, s, OCH3); 
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13C (100 MHz, CDCl3) G 156.8, 156.4, 138.1, 129.8, 129.2, 128.8, 
126.5, 123.3, 114.1, 69.7, 61.3, 55.3. Mass spec. (ESI): calcd. 
m/z 2792.0944 [C16H15ClNO2+Na]+; found: 292.0934. IR (neat, 
cm-1): 1739. 
3-(4-Methylphenyl)-5-phenyloxazolidin-2-one (6i): Obtained 
as a white solid after purification by flash chromatography using 
a solvent system of hexane±EtOAc (9:1) (68 mg, 32%). M.p. 96±
98 oC (lit. 98±100 oC).[5a] 1H NMR (400 MHz, CDCl3) G 7.43±7.41 
(7H, m, ArH), 7.18 (2H, d, J 8.0 Hz, ArH), 5.62 (1H, t, J 8.0 Hz, 
CHO), 4.35 (1H, t, J 8.0 Hz, CH2N), 3.94 (1H, dd, J 8.0, 7.0 Hz, 
CH2N), 2.32 (3H, s, CH3); 13C (100 MHz, CDCl3) G 153.9, 141.7, 
129.5, 129.3, 128.4, 128.3, 126.6, 121.3, 110.0, 74.0, 52.6, 20.8. 
Mass spec. (ESI): calcd. m/z 276.0995 [C16H15NO2+Na]+; found: 
279.0991. IR (neat, cm-1): 1735. 
3-(4-Methylphenyl)-4-phenyloxazolidin-2-one (7i): Obtained 
as a white solid after purification by flash chromatography using 
a solvent system of hexane±EtOAc (9:1) (63 mg, 30%). M.p. 
106±108 oC (lit. 105±107 oC).[5a] 1H NMR (400 MHz, CDCl3) G 
7.36±7.20 (7H, m, ArH), 7.03 (2H, d, J 8.0 Hz, ArH), 5.35 (1H, 
dd, J 8.0, 6.0 Hz, CHN), 4.76 (1H, t, J 8.0 Hz, CH2O), 4.19 (1H, 
dd, J 8.0, 4.0 Hz, CH2O), 2.23 (3H, s, CH3); 13C (100 MHz, 
CDCl3) G 156.2, 138.3, 134.5, 134.3, 129.5, 129.3, 128.8, 126.3, 
121.1, 69.8, 60.8, 20.8. Mass spec. (ESI): calcd. m/z 276.0995 
[C16H15NO2+Na]+; found: 279.1005. IR (neat, cm-1): 1739. 
3-(4-Fluorophenyl)-4-phenyloxazolidin-2-one (7j): Obtained 
as a white solid in a mixture with 12a after purification by flash 
chromatography using a solvent system of first hexane±EtOAc 
(9:1), then hexane± EtOAc (5:1) (28 mg, 12%). 1H NMR (400 
MHz, CDCl3) G 7.4±7.25 (7H, m, ArH), 6.95±6.93 (2H, m, ArH), 
5.33 (1H, dd, J 12.0, 8.0 Hz, CHN), 4.79 (1H, t, J 8.0 Hz, CH2O), 
4.22 (1H, dd, J 8.0, 6.0 Hz, CH2O); 13C (100 MHz, CDCl3) G 
161.5, 156.1, 137.8, 133.0, 129.2, 129.0, 126.4, 123.0 (d, J 8 
Hz), 115.7 (d, J 23 Hz), 69.8, 61.1; 19F NMR (376 MHz, CDCl3): 
G117.1 (s). Mass spec. (ESI): calcd. m/z 280.0744 
[C15H12FNO2+Na]+; found: 280.0716. 
3-(4-Chlorophenyl)-4-phenyloxazolidin-2-one (7k): Obtained 
as a pale yellow solid in a mixture with 12b after purification by 
flash chromatography using a solvent system of hexane±EtOAc 
(9:1) (22 mg, 10%). 1H NMR (400 MHz, CDCl3) G 7.37±7.29 (7H, 
m, ArH), 7.21 (2H, d, J 8.0 Hz, ArH), 5.36 (1H, dd, J 12.0, 8.0 Hz, 
CHN), 4.79 (1H, t, J 8.0 Hz, CH2O), 4.21  (1H, dd, J 8.0, 6.0 Hz, 
CH2O); 13C (100 MHz, CDCl3) G 155.8, 137.7, 135.6, 129.7, 
129.6, 128.9, 126.2, 121.9, 69.8, 60.6. Mass spec. (ESI): calcd. 
m/z 296.0449 [C15H12ClNO2+Na]+; found: 296.0453. 
3-(4-Bromophenyl)-4-phenyloxazolidin-2-one (7l): Obtained 
as a yellow solid in a mixture with 12c after purification by flash 
chromatography using a solvent system of hexane±EtOAc (9:1) 
(26 mg, 10%). M.p. 132±135 oC (lit. 134±137 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.37±7.37 (9H, m, ArH), 5.35 (1H, dd, J 8.0, 
6.0 Hz, CHN), 4.79 (1H, t, J 8.0 Hz, CH2O), 4.21 (1H, dd, J 8.0, 
6.0 Hz, CH2O); 13C (100 MHz, CDCl3) G 156.2, 132.7, 131.8, 
130.0, 129.5, 128.5, 126.0, 123.7, 122.2, 67.2, 61.8. Mass spec. 
(ESI): calcd. m/z 318.0124 [C15H12BrNO2+H]+; found: 318.0130. 
3-(4-Methoxyphenyl)-5-chloromethyloxazolidin-2-one (6o): 
Obtained as a yellow solid after purification by flash 
chromatography using a solvent system of hexane±EtOAc (3:1) 
(160 mg, 80%). M.p. 106±108 oC (lit. 105±106 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.43 (2H, d, J 8.0 Hz, ArH), 6.92 (2H, d, J 
8.0 Hz, ArH), 4.89±4.83 (1H, m, CHO), 4.17±4.10 (2H, m, CH2N), 
3.79 (3H, s, OCH3), 3.78±3.72 (2H, m, CH2Cl); 13C (100 MHz, 
CDCl3) G 156.6, 154.2, 130.9, 120.4, 114.3, 70.8, 55.5, 48.7, 
44.6. Mass spec. (ESI): calcd. m/z 264.0398 [C11H12ClNO3+Na]+; 
found: 264.0395. IR (neat, cm-1): 1728. 
3-(4-Methylphenyl)-5-chloromethyloxazolidin-2-one (6p): Ob- 
tained as a pale yellow solid after purification by flash 
chromatography using a solvent system of hexane±EtOAc (3:1) 
(170 mg, 83%). M.p. 104±106 oC (lit. 104±107 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.42 (2H, d, J 8.0 Hz), 7.19 (2H, d, J 8.0 Hz), 
4.89±4.82 (1H, m, CHO), 4.15 (1H, t, J 8.0 Hz, CH2N), 3.92 (1H, 
dd, J 12.0, 8.0 Hz, CH2N), 3.89 (1H, dd, J 12.0, 4.0 Hz, CH2Cl), 
3.73 (1H, dd, J 12.0, 8.0 Hz, CH2Cl), 2.32 (3H, s, CH3); 13C (100 
MHz, CDCl3) G 154.0, 135.2, 134.1, 129.6, 118.4, 70.8, 48.3, 
44.5, 20.7. Mass spec. (ESI): calcd. m/z 226.0629 
[C11H13ClNO2+H]+; found: 226.0630. IR (neat, cm-1): 1732. 
3-(4-Fluorophenyl)-5-chloromethyloxazolidin-2-one (6q): 
Obtained as a pale yellow solid after purification by flash 
chromatography using a solvent system of hexane±EtOAc (5:1) 
(125 mg, 67%). 1H NMR (400 MHz, CDCl3) G 7.51 (2H, dd, J 8.0, 
4.0 Hz, ArH), 7.09 (2H, t, J 8.0 Hz, ArH), 4.91±4.85 (1H, m, 
CHO), 4.16 (1H, t, J 8.0 Hz, CH2N), 3.96 (1H, dd, J 8.0, 4.0 Hz, 
CH2N), 3.81 (1H, dd, J 12.0, 4.0 Hz, CH2Cl), 3.75 (1H, dd, J 12.0, 
8.0 Hz, CH2Cl); 13C (100 MHz, CDCl3) G 159.5 (d, J 244.5 Hz), 
154.0, 133.9 (d, J 3.2 Hz), 120.2 (d, J 8.1 Hz), 115.9 (d, J 22.6 
Hz), 70.8, 48.4, 44.5. 19F NMR(376 MHz, CDCl3): G117.8 (s). 
Mass spec. (ESI): calcd. m/z 252.0198 [C10H9ClFNO2+Na]+; 
found: 252.0195. 
3-(4-Chlorophenyl)-5-chloromethyloxazolidin-2-one (6r): 
Obtained as an orange solid after purification by flash 
chromatography using a solvent system of hexane±EtOAc (1:1) 
(100 mg, 42%). M.p. 129±132 oC (lit. 130±133 oC).[5a] 1H NMR 
(400 MHz, CDCl3) G 7.49 (2H, d, J 8.0 Hz, ArH), 7.34 (2H, d, J 
8.0 Hz, ArH), 4.91±4.85 (1H, m, CHO), 4.14 (1H, t, J 8.0 Hz, 
CH2N), 3.93 (1H, dd, J 8.0, 4.0 Hz, CH2N), 3.79 (1H, dd, J 12.0, 
4.0 Hz, CH2Cl), 3.75 (1H, dd, J 12.0, 8.0 Hz, CH2Cl); 13C (100 
MHz, CDCl3) G 153.7, 136.3, 129.6, 129.1, 119.4, 70.8, 48.0, 
44.5. Mass spec. (ESI+): calcd.m/z 267.9903 
[C10H9Cl2NO2+Na]+; found: 267.9905. IR (neat, cm-1): 1741. 
3-(4-Bromophenyl)-5-chloromethyloxazolidin-2-one (6s): 
Obtained as a yellow solid after purification by flash 
chromatography using a solvent system of first hexane±EtOAc 
(3:1), then hexane±EtOAc (2:1) (92 mg, 36%). M.p. 126±128 oC 
(lit. 125±128 oC).[5a] 1H NMR (400 MHz, CDCl3) G 7.51±7.44 (4H, 
m, ArH), 4.92±4.86 (1H, m, CHO), 4.15 (1H, t, J 8.0 Hz, CH2N), 
3.94 (1H, dd, J 8.0, 4.0 Hz, CH2N), 3.80 (1H, dd, J 12.0, 4.0 Hz, 
CH2Cl), 3.75 (1H, dd, J 12.0, 8.0 Hz, CH2Cl); 13C (100 MHz, 
CDCl3) G 153.7, 132.7, 132.1, 119.7, 117.3, 70.8, 48.0, 44.4. 
Mass spec. (ESI+): calcd. m/z 311.9397 [C10H9BrClNO2+Na]+; 
found: 311.9389. IR (neat, cm-1):  1732. 
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